HIV Comorbidities 2019

 

HIV-Comorbidities-2019-Banner

HIV Co-Morbidities 2019 Web Buttons

About the Program:

Target Audience:

This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HIV infection.

Back to Top

Learning Objectives:

Upon completion of the program, participants should be able to:

  • Describe the impact of co-morbid conditions, including those associated with aging, HIV and ART, on patients with HIV infection
  • Compare and contrast major ARV guideline recommendations for managing patients with HIV and comorbid conditions and discuss the relative advantages and disadvantages of different approaches
  • Apply in clinical practice multidisciplinary approaches for reducing the burden of complex co-morbid conditions in patients with HIV to prevent morbidity and mortality and addressing the issue of potential drug-drug interactions
  • Provide optimal care to older patients with HIV infection, including the assessment and management of co-morbid conditions associated with an aging population
  • Apply knowledge and skills for selecting and monitoring the most effective long-term ARV therapy for patients with co-morbid conditions

Release Date: August 30, 2019

Expiration Date: August 30, 2020

Estimated time to complete each Module: 30 minutes (4 hours for complete program)

Media: Internet

Computer System Requirements: Internet Connection and Browser

Back to Top

Faculty:

Graeme Moyle, MD, MB, BS (Co-Director)
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom

Paul Sax, MD (Co-Director)
Clinical Director Division of Infectious Diseases 
Brigham and Womens Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Oluwatoyin M. Adeyemi, MD
Associate Professor of Medicine
Rush Medical College
Attending Physician of Infectious Diseases
Cook County Health and Hospitals System
Chicago, Illinois

Pablo Tebas, MD
Professor of Medicine Hospital of the University of Pennsylvania
Director, Adult AIDS Clinical Trials Unit (ACTU)
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania


Back to Top

Joint Accreditation Statement:

Jointly-Accredited-Provider-TM_1000x636  In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
Back to Top

Credit Designation:

Case Module 1 (Bone Density):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case Module 2 (Cardiovascular):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case Module 3 (Weight Gain and NAFLD/NASH): 
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case Module 4 (Renal):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case Module 5 (Diabetes Mellitus):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case Module 6 (Neurocognitive Issues):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case Module 7 (Malignancy): 
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case Module 8 (Frailty):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Back to Top

Disclosure of Conflicts of Interest:

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Graeme Moyle, MD:
  • Consulting Fees: Gilead, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents: TheraTechnologies, Merck
Paul Sax, MD:
  • Consulting Fees: Abbvie, BMS, Gilead, GSK/ViiV, Janssen, Merck
  • Contracted Research: NIH, BMS, Gilead, GSK/ViiV, Merck
  • Other (Editorial Boards): Medscape, UpToDate, Open Forum Infectious Diseases
Oluwatoyin M. Adeyemi, MD:
  • Consulting Fees: Gilead
  • Contracted Research: Gilead
Pablo Tebas, MD:
  • Consulting Fees: Gilead, ViiV, Merck

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers have nothing to disclose.

Back to Top

Method of Participation and Request for Credit:

There are no fees for participating and receiving CME/CE credit for this activity. During the period, August 30, 2019 through August 30, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 14171. Upon registering and successfully completing the activity evaluation, your certificate will be made available immediately.

Back to Top

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Back to Top

Computer System Requirements:

This program requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable version of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player and Real Networks Real One Player. 

Back to Top

 

 

 

 

 

PIM_small

For CME Accreditation Questions, please click HERE 


 

VE logo 300px 

This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs 


  Jointly provided by the Postgraduate Institute for Medicine and ViralEd, Inc.


ViralEd, LLC

http://www.viraled.com/modules/info/hiv_comorbidities_2019.html